Syndax issues $150M public offering pricing

Syndax, a biopharmaceutical company focusing on cancer therapies, has announced the pricing of a $150 million public offering of common stock.

Advertisement

The offering price is $22 for each share of 6,818,182 shares of stock. Additionally, the company granted underwriters a 30-day option to purchase up to an additional 1,022,727 shares of common stock, according to a Dec. 7 Syndax news release provided to Becker’s.

The offering is expected to formally close Dec. 9. 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.